Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05363215 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants
A Phase 1 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT05363215 is a Phase 1 study that has completed, run by Shionogi. The registered enrollment target is 32 participants.
The verdict
NCT05363215, a Phase 1 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The objective of this study is to measure the PK, safety, and tolerability of S-217622 in participants with mild, moderate, or severe renal impairment and in those with normal renal function.
Interventions
- DRUG S-217622
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-08-10 |
| Est. Completion | 2023-04-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05363215
The ClinicalTrials.gov registry entry for NCT05363215 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which S-217622 is the first listed.
NCT05363215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05363215 about?
NCT05363215 is a clinical study titled "A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants". The objective of this study is to measure the PK, safety, and tolerability of S-217622 in participants with mild, moderate, or severe renal impairment and in those with normal renal function.
What is the current status of trial NCT05363215?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2022-08-10. Estimated completion is 2023-04-12.
What interventions are being tested in trial NCT05363215?
The interventions under investigation include: S-217622 (DRUG).
Who is sponsoring clinical trial NCT05363215?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.